|
Jun 12
|
FARXIGA approved in the US for the treatment of pediatric type-2 diabetes
|
|
Jun 12
|
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
|
|
Apr 9
|
UK pharma companies told to make fewer drugs in draft net zero guidelines
|
|
Apr 8
|
AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor
|
|
Apr 8
|
AstraZeneca's (AZN) Enhertu Gets FDA Nod for Solid Tumors
|
|
Apr 7
|
10 Best Weight Loss Drug Stocks to Buy Now
|
|
Apr 6
|
Increases to CEO Compensation Might Be Put On Hold For Now at AstraZeneca PLC (LON:AZN)
|
|
Apr 6
|
ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors
|
|
Apr 6
|
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors
|
|
Apr 5
|
15 Most Densely Populated Cities in Europe
|
|
Apr 5
|
Astrazeneca (AZN) Advances But Underperforms Market: Key Facts
|
|
Apr 5
|
AstraZeneca's (AZN) Imfinzi Improves Survival in SCLC Study
|
|
Apr 5
|
Pharma Stock Roundup: AZN Voydeya Gets FDA Nod, MRK KRAS Inhibitor Enters Phase III
|
|
Apr 5
|
IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial
|
|
Apr 5
|
‘Pioneering’ lung cancer drug offers hope for patients
|
|
Apr 5
|
Trending tickers: AMD, Shell, AstraZeneca, HubSpot
|
|
Apr 5
|
UPDATE 2-AstraZeneca's Imfinzi improves survival in late-stage lung cancer trial
|
|
Apr 3
|
Biden and Senator Sanders to highlight efforts lower cost of asthma inhalers
|
|
Mar 30
|
20 Countries with the Highest Age Dependency Ratio in the World
|
|
Mar 28
|
Pharma Stock Roundup: ABBV & NVO's New M&As, FDA Nod to JNJ & MRK PAH Drugs
|